NCT06245408进行中（未招募）3 期
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen
- 入组人数
- 434
- 试验地点
- 272
- 主要终点
- Change from baseline in Diary for Assessing Sjogren's Patient Reported Index (DASPRI ) score
研究概览
简要总结
Primary Objective:
To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state
Secondary Objectives:
- To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS.
- To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS
- To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
详细描述
Acquired from Horizon in 2024.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with SS by meeting the 2016 ACR/EULAR Classification Criteria
- •Have an ESSPRI score of ≥ 5 at screening.
- •Have an ESSDAI score of < 5 at screening.
- •Positive for either anti-Ro autoantibodies or RF, or both at screening (as per the definition of the standard central laboratory test).
- •Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min.
- •Vaccinated against SARS-CoV-2 according to current local authority guidelines at least 2 weeks prior to screening unless participant refuses vaccination.
- •Meets all of the following tuberculosis (TB) criteria:
- •No history of latent or active TB prior to screening, except for latent TB with documented completion of locally appropriate treatment.
- •No signs or symptoms suggestive of active TB from medical history or physical examination.
- •No recent (≤ 12 weeks of screening) close contact with a person with active TB (close contact is defined as ≥ 4 hours/week OR living in the same household OR in a house where a person with active TB is a frequent visitor).
- •Negative Interferon Gamma Release Assay (IGRA) test result for TB at screen unless previously treated as per Inclusion Criterion. Participants with an indeterminate test result can repeat the test, but if the repeat test is also indeterminate, they are excluded.
- •A chest radiograph (obtained during the screening period or any time within 12 weeks prior to screening) with no evidence of current active TB or other infection, or prior TB, malignancy, or clinically significant abnormalities suggesting an active process (unless due to SS).
排除标准
- •Individuals with medical history of confirmed deep venous thrombosis, pulmonary embolism, or arterial thromboembolism within 2 years of screening.
- •History or presence of concomitant polymyositis or dermatomyositis or systemic sclerosis.
- •Active malignancy or history of malignancy within the last 5 years, except as follows:
- •In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to screening; OR
- •Cutaneous basal cell carcinoma following presumed curative therapy.
- •Individuals who are pregnant or lactating or planning to become pregnant during the study.
- •Individuals with known history of severe allergy or reaction to any component of the IP formulation or to any other biologic therapy.
- •Individuals with any severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder or any other condition that, in the opinion of the Investigator, would place the individual at unacceptable risk of complications, interfere with evaluation of the IP, or confound the interpretation of participant safety or study results.
- •Individuals who have a positive test for, or have been treated for, hepatitis B, hepatitis c or HIV infection.
- •Individuals with a positive test for SARS-CoV-2 on the day of randomization or symptoms suggestive of SARS-CoV-2 at randomization or significant exposure to coronavirus disease 2019 (COVID-19) within 10 calendar days prior to randomization.
- •Individuals with:
- •A history of more than one episode of herpes zoster and/or opportunistic infections in the last 12 months, with the exception of non-invasive herpes simplex at any site, oral candidiasis, vaginal candidiasis, or cutaneous fungal infections, which are permitted within the prior 12 months unless of unusual severity.
- •Active infection requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring IV antibiotics within 12 months prior to screening.
研究组 & 干预措施
Dazodalibep Dose 1
Experimental
Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
干预措施: Dazodalibep (Drug)
Dazodalibep Dose 2
Experimental
Participants will be administered dose 2 of dazodalibep by IV infusion.
干预措施: Dazodalibep (Drug)
Placebo
Placebo Comparator
Participants will be administered placebo by IV infusion.
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Diary for Assessing Sjogren's Patient Reported Index (DASPRI ) score
时间窗: At week 48
Change from baseline in ESSPRI score
时间窗: At Week 48
次要结局
- Proportion of participants achieving ESSPRI [1.5] response(At Week 48)
- Number of participants With Adverse Events of Special Interest (AESIs)(Baseline (Day 1) to Week 56)
- Proportion of participants achieving meaningful improvement in DASPRI(At Week 48)
- Change from baseline in Patient-Reported Outcomes Measurement Information System Fatigue-Short Form 10a (PROMIS-Fatigue SF-10a)(At Week 48)
- Change from baseline in DASPRI Pain(At Week 48)
- Change from baseline in ESSPRI Pain(At Week 48)
- Change from baseline in ESSPRI fatigue domain score(At Week 48)
- Change from baseline in 36-item Short Form Survey (SF-36) Physical Component Summary (PCS) score(At Week 48)
- Change from baseline in DASPRI total score(At week 12 and week 24)
- Change from baseline in total stimulated salivary flow(At Week 48)
- Change from baseline in DASPRI Dryness(At Week 48)
- Change from baseline in ESSPRI Dryness(At Week 48)
- Change from baseline in ESSPRI total score(At week 12, Week 24)
- Change from baseline in DASPRI Fatigue(At Week 48)
- Number of participants With Treatment Emergent Adverse Events (TEAEs)(Baseline (Day 1) to Week 56)
- Number of participants With Treatment Emergent Serious Adverse Events (TESAEs)(Baseline (Day 1) to Week 56)
研究者
研究点 (272)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivitySjogren's SyndromeNCT06104124Amgen651
已完成
3 期
Confirmatory Study of DSP-5423P in Patients With SchizophreniaSchizophreniaNCT02287584Sumitomo Pharma Co., Ltd.580
已完成
3 期
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic DermatitisAtopic DermatitisNCT02595073Taro Pharmaceuticals USA124
已完成
3 期
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial FlutterAtrial FibrillationAtrial FlutterNCT00115791Astellas Pharma Inc276
已完成
3 期
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque PsoriasisPlaque PsoriasisNCT02618759Taro Pharmaceuticals USA119